Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.79 |
| ▸ | HTR2B | P41595 | 8/20 | 0.79 |
| ▸ | HTR2A | P28223 | 6/20 | 0.79 |
| ▸ | PNMT | P11086 | 4/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471722 | 1.00 | HTR2C (0.79) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL21762550 | 0.88 | HTR2C (1.00) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Hydrochloric Acid SCHEMBL21753252 | 0.87 | HTR2C (0.97) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL6189510 | 0.87 | HTR2C (0.79) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL31463205 | 0.84 | HTR2C (0.60) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Hydrochloric Acid SCHEMBL31084068 | 0.83 | HTR2C (0.58) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL17585094 | 0.83 | HTR2C (0.55) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL17585098 | 0.83 | HTR2A (0.55) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL829320 | 0.81 | HTR2C (0.53) | HTR2CHTR2BHTR2APNMTCD44 | |
| SCHEMBL12682948 | 0.81 | HTR2C (0.53) | HTR2CHTR2BHTR2APNMTCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | Boehringer Ingelheim International GmbH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| WO-2016041845-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2265587-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009105206-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | QDPR, RECQL, TPMT | HTR2C 349/4885HTR2B 443/4885HTR2A 569/4885 |
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | HTR2C 37/4885HTR2B 51/4885HTR2A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.